Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21472135 | 0.83 | MTNR1A (0.33) | MTNR1AMTNR1B | |
| SCHEMBL17127617 | 0.78 | PTGS1 (0.38) | PTGS1PTGS2MTNR1ASMN1; SMN2NPSR1 | |
| SCHEMBL13054417 | 0.77 | FABP4 (0.39) | PTGS1PTGS2FABP3FABP4FABP5 | |
| SCHEMBL17178032 | 0.77 | PTGS1 (0.33) | PTGS1PTGS2HTR2AHTR2CHTR2B | |
| SCHEMBL26700316 | 0.76 | EIF4A3 (0.34) | PTGS1PTGS2SMN1; SMN2HTR2AHTR2C | |
| SCHEMBL18353323 | 0.73 | CYP1A2 (0.36) | PTGS1PTGS2 | |
| SCHEMBL19155805 | 0.73 | PARP1 (0.34) | PTGS1PTGS2FABP3FABP4FABP5 | |
| SCHEMBL801756 | 0.72 | PTGS1 (0.30) | PTGS1PTGS2 | |
| SCHEMBL21135053 | 0.69 | OGA (0.32) | — | |
| SCHEMBL21134900 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | PTGS1 1646/4885PTGS2 2927/4885FABP3 4471/4885 |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | PTGS1 1646/4885PTGS2 2927/4885FABP3 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.